Healthcare / BiotechnologyKOSDAQ
$3235.00
+80.00 (+2.38%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $1.0B · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$55.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-19.7%
↓Gross Margin
76.2%
↑Debt/Equity
0.32
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-5.0%
FCF CAGR
+34.5%
FCF margin
1.4%
FCF / Net income
-0.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $74.05B · net income $-18.96B · FCF $1.03B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $74.05B | $74.05B | $58.17B | $52.81B | $86.28B |
| Net Income | $-18.96B | $-18.96B | $-8.56B | $-164.0M | $-1.01B |
| EBITDA | $-10.74B | $-10.74B | $-5.97B | $7.27B | $6.00B |
| EPS | — | — | -510.00 | -10.00 | -70.00 |
| Gross Margin | 76.2% | 76.2% | 71.0% | 67.7% | 63.4% |
| Operating Margin | -11.6% | -11.6% | -22.3% | -2.2% | 7.5% |
| Net Margin | -25.6% | -25.6% | -14.7% | -0.3% | -1.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.32 | 0.32 | 0.31 | 0.60 | 1.30 |
| Current Ratio | 1.20 | 1.20 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.03B | $1.03B | $-20.60B | $1.19B | $421.7M |
| Returns | |||||
| ROE | -19.7% | -19.7% | -7.7% | -0.2% | -1.4% |
| Valuation | |||||
| EV/EBITDA | — | — | — | 33.16 | 72.26 |
| P/B | 0.57 | 0.57 | 1.70 | 2.45 | 5.08 |
| Growth & Yield | |||||
| Revenue Growth | 27.3% | 27.3% | 10.1% | -38.8% | — |
| EPS Growth | — | — | -5000.0% | 85.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-56.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-510.00 → n/d
Residual
-56.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.